Risk-Based Management of Follicular Lymphoma: Case 1
Risk-Based Management of Follicular Lymphoma
June 2015
A 75-year-old female presents to her physician with bilateral inguinal adenopathy. She is otherwise healthy.
- Laboratory findings: CBC count and LDH WNL
- CT scan shows scattered adenopathy in the pelvis, mesentery, retroperitoneal regions. The largest lymph node is 2.6 cm.
- Chest radiography, normal
- Bone marrow biopsy is negative
- Excisional biopsy, IHC staining for CD10 shows grade 1 follicular lymphoma
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
August 16th 2024The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.
Read More
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
